Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.

Slides:



Advertisements
Similar presentations
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlikeLicense. Your use of this material constitutes acceptance of that license.
Advertisements

ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
Donald T. Simeon Caribbean Health Research Council
Chapter 3 Program Management and Project Evaluation Professor Hossein Saiedian McGraw-Hill Education ISBN
Need to Invest Investment Objectives and Case for Change Determine Potential Value for Money Strategic Case: Economic Case: Financial Case: Affordability.
POC INR Testing Rural and Remote Session 2015 CADTH SYMPOSIUM Janice Mann MD Knowledge Mobilization, CADTH.
Economic Analysis Concepts. 2 Is the project justified ?- Are benefits greater than costs? Which is the best investment if we have a set of mutually exclusive.
EVAL 6970: Cost Analysis for Evaluation Dr. Chris L. S. Coryn Nick Saxton Fall 2014.
Economic Analysis and Management Todd Wagner, PhD.
Quality improvement for asthma care: The asthma care return-on-investment calculator Ginger Smith Carls, M.A., Thomson Healthcare (Medstat) State Healthcare.
Quality improvement for asthma care: The asthma care return-on-investment calculator Ginger Smith Carls, M.A., Thomson Healthcare (Medstat) State Healthcare.
Costs and Cost Effectiveness HINF Medical Methodologies Session 15.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
Initiating and Planning Systems Development Projects.
Lec 21, Project Evaluation Part 1: Impact analysis General characteristics of benefits and costs Estimates of economic costs and benefits A framework for.
VI-Economic Evaluation of Facility Investments 1. Project Life Cycle and Economic Feasibility 2.Basic Concepts of Economic Evaluation 3.Costs and Benefits.
Economic Challenges and New Medical Technologies Laurence Baker, Ph.D. Stanford University School of Medicine
Session 4: Making a case - ROI and business case for tobacco control ARCH Technical Workshop Bali August 2014 Matt Glover Health Economics Research Group.
PROJECT EVALUATION. Introduction Evaluation  comparing a proposed project with alternatives and deciding whether to proceed with it Normally carried.
Drug and Therapeutics Committee
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Assessing cost-effectiveness – what is an ICER?- Incremental analysis
Stephane Larocque – Consulting Practice Leader, Impact Infrastructure A DECISION MAKING FRAMEWORK FOR SUSTAINABLE INFRASTRUCTURE DEVELOPMENT 1 ST INTERNATIONAL.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Disease Management: High Risk Groups Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Introduction ► This slide deck provides a suggested framework for the financial evaluation of an investment project. When evaluating any such project,
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Cost-Benefit Analysis Delia Prieto University of Miami December 10, 2011.
Notes for Chapter 6 ECON Benefit cost analysis Many definitions and perspectives  Determines optimal policy from the perspective of either government.
Pharmacoeconomics & Drug Compliance Dr Arif Hashmi.
State Smart Transportation Initiative October 9, 2014 Matthew Garrett Oregon DOT Director Erik Havig Oregon DOT Planning Section Manager.
Measuring Health Systems Performance and NHA: Agenda for Health Services Research and Evaluation Measuring Health Systems Performance and NHA: Agenda for.
ISPOR Methods Guidance A Report of the ISPOR Task Force on Budget Impact Modeling January 21, 2009 Sean D. Sullivan, PhD Pharmaceutical Outcomes Research.
The Systems Analysis Toolkit
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
Considering the Costs of MUS Interventions. Direct Costs v. Opportunity Costs Direct Costs Expenditures and investments to achieve a particular outcome.
Copyright 2010, The World Bank Group. All Rights Reserved. Planning and programming Planning and prioritizing Part 1 Strengthening Statistics Produced.
Opportunity Cost of Capital and Capital Budgeting
COST BENEFIT ANALYSIS- PUBLIC SECTOR INVESTMENTS Lucky Yona.
Building a Business Case for Quality Improvement Glen Copping CFO and Vice-President, Systems Development & Performance Session: BC PSQC D2 Thursday, February.
Measuring Efficiency CRJS 4466EA. Introduction It is very important to understand the effectiveness of a program, as we have discovered in all earlier.
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
CLICK TO ADD TITLE [DATE][SPEAKERS NAMES] The 6th Global Health Supply Chain Summit November , 2013 Addis Ababa, Ethiopia Economic Evaluation of.
CHAPTER TEN Capital Budgeting: Basic Framework J.D. Han.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
Promoting high quality, cost effective drug therapy throughout the Military Health System Identification and Use of Published Health Economic Evaluations.
The financial costs and benefits of alcohol The financial costs and benefits of alcohol Christine Godfrey Department of Health Sciences & Centre for Health.
Software Project Management
1 Cost-Benefit Analysis Public Economics Minda DC. Eduarte.
Risk Sharing Schemes Dr Rafiq Hasan Director of Market Access
Lecture 51 Project Costing Lecture 52 Objectives Define economic feasibility Identify the cost considerations that analysts consider throughout the SDLC.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
TEL2813/IS2820 Security Management Cost-Benefit Analysis Net Present Value Model, Internal Rate of Return Model Return on Investment (Based on Book by.
CRJS 4466 PROGRAM & POLICY EVALUATION LECTURE #6 Evaluation projects Questions?
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Balancing revenues and costs for orphan drugs: a case study Aidan Hollis University of Calgary: Department of Economics and O’Brien Institute of Public.
Health Policy Issues An Economic Perspective Copyright © 2015 Foundation of the American College of Healthcare Executives. Not for sale.
Understanding Health Economics Nicola Cooper, PhD Professor of Healthcare Evaluation Research Department of Health Sciences University of Leicester
Budget & cost accounting
Cost effectiveness Analysis: Valuing Health; Valuing Research!
HEALTH ECONOMICS BASICS
Cornerstone Research Group Inc.
Cost Effective Studies
Strategies to incorporate pharmacoeconomics into pharmacotherapy
Evaluation and impact of HTA on private health insurance Dr Ehab Abul-Magd *President of the Afro-Asian congress for Medical Insurance & Managed Care.
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.

Outline  Budget impact analysis (BIA)  Return on investment (ROI) 2

BUDGET IMPACT ANALYSIS (BIA) 3

4 Definition of BIA  Budget Impact Analysis (BIA) is an essential part of a comprehensive economic assessment of a health care technology  The impact of implementing the intervention on healthcare budget and on other constraints should be clearly and separately identified.  Increasingly required, along with economic evaluation (EE), prior to formulary approval or reimbursement.

5 Adapted from: Brosa M, Gisbert R, Rodrez Barrios JM y Soto J. Pharmacoeconomics Spanish Research Articles 2005; 2:

6 The Purpose of BIA  To estimate the financial consequences of adoption and diffusion of a new health care intervention within a specific health care setting given inevitable resource constraints  To predict how a change in the mix of drugs and other therapies used to treat a particular health condition will impact the trajectory of spending on that condition  To use for budget planning, forecasting and computing the impact of health technology changes on premiums in health insurance schemes

7 Users of BIA  Those who manage and plan for health care budgets administrators of national regional health care programs administrators of private insurance plans administrators of health care delivery organizations employers who pay for employee health benefits  Each has a need for clearly presented information on the financial impact of alternative health care interventions.

8 BIA and EE  BIA should be viewed as complementary to EE, not as a variant or replacement.  EE evaluates the costs and outcomes of alternative technologies over a specified time horizon to estimate their economic efficiency.  BIA addresses the financial stream of consequences related to the uptake and diffusion of technologies to assess their affordability.

9 BIA and EE  EE and BIA share many of the same data elements and methodological requirements.  However, there are important differences in how these data and methods are incorporated into the models because of their different intended use.

BIA VS EE 10 DetailsBIAEconomic evaluation Concept  Affordability  Value for money Objective  Financial impact of introducing a technology  Economic efficiency of alternative technologies Study timeframe  Budget holder preference (usually 1-5 ​​years)  Preferably lifetime Health outcomes  Excluded  Included (e.g. quality- adjusted life years) Perspective  Budget holder/Manager  Society/Third payers/other

BIA VS EE 11 DetailsBIAEconomic evaluation Comparison  Scenarios in which they can design the degree of incorporation of the new technology in the population with a mixture of utilization  Specific technologies: a new technology will be used throughout cohort intervention Study population  Open cohort  Close cohort Discounting  Not recommended  Highly recommended Presenting result  Total and incremental annual costs  Incremental cost per unit of health outcome achieved Generalization of results  Inadequate: impact studies budget are designed to specific circumstances  Possible, with limitations

What is the budget impact methodological specification?  Presented the budget impact in a manner that is relevant to the decision problem and the needs of the intended decision maker  Disaggregate and reflect the costs to all parties as a result of implementation of the intervention government and social insurance budgets households and direct out of pocket expenses third-party payers external donors, etc.  Annual budgeting is preferable 12

Example: BIA on Stem Cell Transplantation for Severe Thalassemic Patients 13

RETURN ON INVESTMENT (ROI) 14

What is ROI?  A financial measure to determine benefit to the organization  A form of cost-benefit analysis that measures the costs of a program versus the financial return from that program 15

Why is ROI important for decisions?  The financial impacts of the implementing the interventions  Effectiveness of interventions in terms of their financial return 16

ROI Analysis  A measure used to: Evaluate the efficiency (net financial benefits) of the investment Compare the efficiency of different investments  Formula: For instance, a $100 investment earns $150 in benefit program, then ROI = 50% 17 Total benefits – Total costs Total costs

What is the ROI methodological specification?  ROI is useful when costs and benefits are tangible.  It is usually calculated from the perspective of the organization implementing the program.  An analysis over a year, future costs and benefits need to be discounted. 18

Considerations for using ROI  Many costs and benefits in the future are difficult to quantify.  Benefits in health intervention (e.g. case averted and QALY gained) are not easy to value in the monetary unit.  ROI could not value the essential of public health interventions. 19

20 Thank you very much, any question?